[ad_1]
Last update:
Divies Laboratories Limited has been given a ‘bye’ rating by the City, the target price has been fixed at Rs 7,750. The company’s market cap is Rs 1.63 lakh crore and EPS was Rs 83.20.
The company has registered a revenue of Rs 2,357 crore on a standalone basis in the April-June 2025 quarter.The market concerns about the generic version of the drug entrysto used to treat the heart rate of Novartis are gradually decreasing. Divise laborators supply activated pharmaceutical ingredients (APIs) for this medicine. It is estimated that Entresto API will remain the largest product in the company’s innovator Custom synthesis (CS) portfolio. Its contribution is estimated to be about 40 percent in CS Revenue and about 20 percent in consolidated revenue.
Divize share target price
The city has fixed the target price of Rs 7,750, giving the division share ‘by’ rating, which is about 26 percent more than Rs 6,150.70 on BSE on Friday, August 22. If we talk about the opinion of 30 analysts covering this stock, then 11 have given it ‘bye’, 6 ‘hold’ and 13 have given ‘SAIL’ ratings. The face value of the share is Rs 2. The 52-week high of this stock on BSE is Rs 7,077.70 and the lower level is Rs 4,831.
Divies quarterly results
The company recorded a revenue of Rs 2,357 crore on a standalone basis in the April-June 2025 quarter, while the net profit was Rs 557 crore. Earnings per share (EPS) was Rs 20.95 in this quarter. In FY 2025, the company’s standalone revenue was Rs 9,198 crore and net profit was Rs 2,209 crore, while the EPS of the entire year was recorded at Rs 83.20.
(Disclaimer: Stocks mentioned here are based on the advice of brokerage houses. If you want to invest money in any of these, consult the first certified Investment Advisor. AyraNews24x7 will not be responsible for any kind of profit or loss.)
[ad_2]
